Department of Cardiology, Zhongshan Hospital, Fudan University.
Shanghai Institute of Cardiovascular Diseases.
Int Heart J. 2021 Jan 30;62(1):162-170. doi: 10.1536/ihj.20-384. Epub 2021 Jan 16.
High-mobility group box 1 (HMGB1) is increased in the myocardium under pressure overload (PO) and is involved in PO-induced cardiac remodeling. The mechanisms of the upregulation of cardiac HMGB1 expression have not been fully elucidated. In the present study, a mouse transverse aortic constriction (TAC) model was used, and an angiotensin II (Ang II) type 1 (AT1) receptor inhibitor (losartan) or Ang II type 2 (AT2) receptor inhibitor (PD123319) was administrated to mice for 14 days. Cardiac myocytes were cultured and treated with Ang II for 5 minutes to 48 hours conditionally with the blockage of the AT1 or AT2 receptor. TAC-induced cardiac hypertrophy was observed at 14 days after the operation, which was partially reversed by losartan, but not by PD123319. Similarly, the upregulated HMGB1 expression levels observed in both the serum and myocardium induced by TAC were reduced by losartan. Elevated cardiac HMGB1 protein levels, but not mRNA or serum levels, were significantly decreased by PD123319. Furthermore, HMGB1 expression levels in culture media and cardiac myocytes were increased following Ang II treatment in vitro, positively associated with the duration of treatment. Similarly, Ang II-induced upregulation of HMGB1 in vitro was inhibited by both losartan and PD123319. These results suggest that upregulation of HMGB1 in serum and myocardium under PO, which are partially derived from cardiac myocytes, may be induced by Ang II via the AT1 and AT2 receptors. Additionally, amelioration of PO-induced cardiac hypertrophy following losartan treatment may be associated with the reduction of HMGB1 expression through the AT1 receptor.
高迁移率族蛋白 B1(HMGB1)在压力超负荷(PO)下心肌中增加,并参与 PO 诱导的心脏重塑。心脏 HMGB1 表达上调的机制尚未完全阐明。在本研究中,使用了小鼠主动脉缩窄(TAC)模型,并在 14 天内给予血管紧张素 II(Ang II)1 型(AT1)受体抑制剂(氯沙坦)或 Ang II 2 型(AT2)受体抑制剂(PD123319)。培养心肌细胞并在 5 分钟至 48 小时条件下用 AT1 或 AT2 受体阻断剂处理 Ang II。TAC 术后 14 天观察到心脏肥大,氯沙坦部分逆转,但 PD123319 未逆转。同样,TAC 诱导的血清和心肌中 HMGB1 表达上调水平也被氯沙坦降低。PD123319 显著降低了心脏 HMGB1 蛋白水平,但不降低其 mRNA 或血清水平。此外,HMGB1 表达水平在体外培养的培养基和心肌细胞中随 Ang II 处理时间的延长而增加,与处理时间呈正相关。同样,体外 Ang II 诱导的 HMGB1 上调也被氯沙坦和 PD123319 抑制。这些结果表明,PO 下血清和心肌中 HMGB1 的上调,部分来源于心肌细胞,可能是由 Ang II 通过 AT1 和 AT2 受体诱导的。此外,氯沙坦治疗后 PO 诱导的心脏肥大的改善可能与 AT1 受体减少 HMGB1 表达有关。